Search results
Neurocrine Biosciences, Inc. (NBIX): Worth Consideration At $140.71 – Stocks Register
Stocks Register· 6 days agoTaking a look at stock we notice that its last check on previous day was $139.83. Company’s P/E ratio for the trailing 12 months is 38.68. Considering stock
BMO Capital Markets Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $138.00
ETF DAILY NEWS· 4 days agoNeurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target increased by BMO Capital Markets from $129.00 to $138.00 in a research report report ...
Neurocrine Biosciences, Inc. [NBIX] Investment Appeal on the Rise – Knox Daily
Knox Daily· 2 days agoprice target was increased to $170 from $140. Deutsche Bank began covering NBIX with “Buy” recommendation on December 12, 2023. Price ...
Q2 2024 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Decreased by Analyst
ETF DAILY NEWS· 3 days agoNeurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) – Stock analysts at Wedbush dropped their Q2 2024 earnings per share estimates for shares of Neurocrine ...
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Zacks via Yahoo Finance· 3 hours agoCost & Other...Holdings Even though ETFs offer diversified exposure that minimizes single stock...
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
Investor's Business Daily· 6 days agoAccording to TechCrunch, the price tag is $700 million. Run.ai helps developers use AI tools more...
Disney, Ferrari Highlight A Week Of Fast-Moving Stocks
Investor's Business Daily· 7 days agoEarnings season moves into final innings, some fast-moving names led by Disney, Ferrari and...
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
Investor's Business Daily· 7 days agoThe Nasdaq regained its 50-day line Friday. The other indexes hit resistance.